MA

Mahsa Keshavarz-Fathi


MD, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran



  • Darbeheshti F, Kadkhoda S, Keshavarz-Fathi M, Razi S, Bahramy A, Mansoori Y, et al. Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness. BMC Cancer. 2022;22(1):668. https://doi.org/10.1186/s12885-022-09761-4
  • Keshavarz-Fathi M, Sanati G, Sadr M, Mohebbi B, Ziaee V, Rezaei N. Aberrant DNA methylation of the promoters of JAK2 and SOCS3 in juvenile systemic lupus erythematosus. European Cytokine Network. 2021;32(3):48-54.
    https://doi.org/10.1684/ecn.2021.0469
  • Keshavarz-Fathi M, Sanati G, Sadr M, Mohebbi B, Ziaee V, Rezaei N. DNA Methylation of CD70 Promoter in Juvenile Systemic Lupus Erythematosus. Fetal and Pediatric Pathology. 2021;41(1):58-67.
    https://doi.org/10.1080/15513815.2020.1764681
  • Keshavarz-Fathi M*, Rezaei N. Cancer Immunoprevention: Current Status and Future Directions. Archivum immunologiae et therapiae experimentalis. 2021;69(1):3.
    https://doi.org/10.1007/s00005-021-00604-x
  • Razavi A, Keshavarz-Fathi M, Pawelek J, Rezaei N. Chimeric antigen receptor T-cell therapy for
    melanoma. Expert review of clinical immunology. 2021:1-15.
    https://doi.org/10.1080/1744666X.2021.1880895
  • Seyedmirzaei H, Keshavarz-Fathi M, Razi S, Gity M, Rezaei N. Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2). Journal of Oncology Pharmacy Practice. 2021 Jul;27(5):1235-1244.
    https://doi.org/10.1177/1078155221991636
  • Sheida F, Razi S, Keshavarz-Fathi M, Rezaei N. The role of myeloid-derived suppressor cells in lung cancer and targeted immunotherapies. Expert Review of Anticancer Therapy. 2022;22(1):65-81.
    https://doi.org/10.1080/14737140.2022.2011224
  • Yazdanpanah N, Keshavarz-Fathi M, Ziaei H, Jaberipour A, Mirbeyk M, Hanaei S, et al. Universal Accreditation System (UAS): An Innovative Education and Research Credit Appraisal by USERN. Acta Medica Iranica. 2022;60(1):1-4.
    https://doi.org/10.18502/acta.v60i1.8321
  • Zargarbashi R, Bagherpour A, Keshavarz-Fathi M, Panjavi B, Bagherpour Zarchi M. Prognosis of Congenital Pseudarthrosis of the Tibia: Effect of Site of Tibial Pseudarthrososis and Fibular Involvement. Journal of Pediatric Orthopaedics. 2021;Publish Ahead of Print. https://doi.org/10.1097/BPO.0000000000001861
  • Sedighzadeh SS, Khoshbin AP, Razi S, Keshavarz-Fathi M, Rezaei N. A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications. Translational Lung Cancer Research. 2021;10(4):1889-916. https://doi.org/10.21037/tlcr-20-1241
  • Pezeshki PS, Moeinafshar A, Ghaemdoust F, Razi S, Keshavarz-Fathi M, Rezaei N. Advances in Pharmacotherapy for Neuroblastoma. Expert Opinion on Pharmacotherapy. 2021 Jul 26:1-22; Epub ahead of print..
    https://doi.org/10.1080/14656566.2021.1953470
  • Makuku R, Khalili N, Razi S, Keshavarz-Fathi M, Rezaei N. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. Journal of Immunology Research. 2021;2021:6661406.
    https://doi.org/10.1155/2021/6661406
  • Hanaei S, Sarzaeim M, YazdanpanahN, Rahimi Pirkoohi Z, Ziaei H, Mohamed K, Samieefar N,
    Keshavarz-Fathi M, Kolahchi Z, Moradian N, MomtazmaneSh S, Seyedpour S, Jaberipour A, Ashkevarian S, Rezaei N. The Hybrid USERN 2020 Congress: New Standards for Events in Practice. Acta Med Iran. 2021:59(1):1-3.
    https://doi.org/10.18502/acta.v59i1.5395
  • Momtazmanesh S, Rahmani F, Delavari F, Vahedi Z, Ebadirad S, Keshavarz-Fathi M, et al. U100: An Innovative USERN Platform for Education and Research Without Borders. Acta Med Iran. 2020;58(1):1-3.
    https://doi.org/10.18502/acta.v58i1.3698
  • Zargarbashi R, Panjavi B, Keshavarz-Fathi M*. Extensive Deep Tissue Involvement in Nicolau Syndrome and Below-Knee Amputation: A Case Report and Literature Review. The International Journal of Lower Extremity Wounds. 2020 Aug 17:1534734620948768.
    https://doi.org/10.1177/1534734620948768
  • Nasrollahzadeh E, Razi S, Keshavarz-Fathi M, Mazzone M, Rezaei N. Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site. Cancer Immunology, Immunotherapy. 2020; 69: 1673–1697.
    https://doi.org/10.1007/s00262-020-02616-6
  • Aghamiri S, talaei S, Roshanzamiri S, Zandsalimi F, Fazeli E, Aliyu M, Kheiry Avarvand O, Ebrahimi Z,
    Keshavarz-Fathi M, Ghanbarian H, Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy. Expert Opinion on Drug Delivery. 2020:1-14.
    https://doi.org/10.1080/17425247.2020.1747429
  • Mahdavi Sharif P, Jabbari P, Razi S, Keshavarz-Fathi M, Rezaei N. Importance of TNF-alpha and its alterations in the development of cancers. Cytokine. 2020;130:155066.
    https://doi.org/10.1016/j.cyto.2020.155066
  • Ebrahimi M, Khalili N, Razi S, Keshavarz-Fathi M, Khalili N, Rezaei N. Effects of lead and cadmium on the immune system and cancer progression. Journal of Environmental Health Science and Engineering. 2020; 18:335–343.
    https://doi.org/10.1007/s40201-020-00455-2
  • Gouravani M, Khalili N, Razi S, Keshavarz-Fathi M, Khalili N, Rezaei N. The NLRP3 inflammasome: a therapeutic target for inflammation-associated cancers. Expert review of clinical immunology. 2020;16(2): 175-187.
    https://doi.org/10.1080/1744666X.2020.1713755
  • Ghaemdoust F, Keshavarz-Fathi M, Rezaei N. Natural killer cells and cancer therapy, what we know and where we are going. Immunotherapy. 2019;11(14):1231-51.
    https://doi.org/10.2217/imt-2019-0040
  • Rahmani F, Keshavarz-Fathi M, Hanaei S, Aminorroaya A, Delavari F, Paryad-Zanjani S, Sadat Ahmadi N, Akbari P, Ashkevarian S, Barghi F, Ebadirad S, Jaberipour A, Kolahi MR, Moallemian M, Pourebrahimi A, Samimiat A, Vahedi Z, Ladi Seyedian S-S, Rezaei N. Universal Scientific Education and Research Network (USERN): Step Strong in Scientific Networking. . Acta Med Iran. 2019;57(1):1-4.
    https://doi.org/10.18502/acta.v57i1.1747
  • Afshari F, Soleyman-Jahi S, Keshavarz-Fathi M, Roviello G, Rezaei N. The promising role of monoclonal antibodies for gastric cancer treatment. Immunotherapy. 2019;11(4):347-64.
    https://doi.org/10.2217/imt-2018-0093
  • Razi S, Baradaran Noveiry B, Keshavarz-Fathi M, Rezaei N. IL-17 and colorectal cancer: From carcinogenesis to treatment. Cytokine. 2019;116:7-12.
    https://doi.org/10.1016/j.cyto.2018.12.021
  • Pastaki Khoshbin A, Eskian M, Keshavarz-Fathi M, Rezaei N. Roles of Myeloid-Derived Suppressor Cells in Cancer Metastasis: Immunosuppression and Beyond. Archivum immunologiae et therapiae experimentalis. 2019;67(2):89-102.
    https://doi.org/10.1007/s00005-018-0531-9
  • Khalili N, Keshavarz-Fathi M, Shahkarami S, Hirbod-Mobarakeh A, Rezaei N. Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2019;25(4):903-17.
    https://doi.org/10.1177%2F1078155218808080
  • Sadeghi M, Keshavarz-Fathi M, Baracos V, Arends J, Mahmoudi M, Rezaei N. Cancer cachexia: Diagnosis, assessment, and treatment. Critical reviews in oncology/hematology. 2018;127:91-104.
    https://doi.org/10.1016/j.critrevonc.2018.05.006
  • Farajzadeh VS, Keshavarz-Fathi M*, Silvestris N, Argentiero A, Rezaei N. The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer. Cytokine & growth factor reviews. 2018;39:46-61.
    https://doi.org/10.1016/j.cytogfr.2018.01.007
  • Khajeh Alizadeh Attar M, Anwar MA, Eskian M, Keshavarz-Fathi M,
    Choi S, Rezaei N. Basic understanding and therapeutic approaches to target toll-like receptors in cancerous microenvironment and metastasis. Medicinal research reviews. 2018;38(5):1469-84.
    https://doi.org/10.1002/med.21480
  • Rezahosseini O, Hanaei S, Hamadani M, Keshavarz-Fathi M, Rezaei N. The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. International Reviews of Immunology. 2018;37(3):165-73.
    https://doi.org/10.1080/08830185.2017.1405396
  • Yousefi H, Yuan J, Keshavarz-Fathi M, Murphy JF, Rezaei N. Immunotherapy of cancers comes of age. Expert review of clinical immunology. 2017;13(10):1001-15.
    https://doi.org/10.1080/1744666X.2017.1366315
  • Jalaeikhoo H, Rajaeinejad M, Keyhani M, Keshavarz-Fathi M. A Case Report of a Metastatic Primary Gastric Lymphoma; Diffuse Large B-Cell or Burkitt Lymphoma? mcijournal. 2017;1(2):32-5.
    http://dx.doi.org/10.21859/mci-01022
  • Hoseinpour P, Olfatbakhsh A, Keshavarz-Fathi M, Beheshtian T, Hashemi EA, Hoseinpour P. Dermatofibrosarcoma Protuberans; Case Report of a Rare Tumor of the Breast. mcijournal. 2017;1(1):26-8.
    http://dx.doi.org/10.21859/mci-010111
  • Zamani MM, Keshavarz-Fathi M, Fakhri-Bafghi MS, Hirbod-Mobarakeh A, Rezaei N, Bahrami A, et al. Survival benefits of dexmedetomidine used for sedating septic patients in intensive care setting: A systematic review. Journal of critical care. 2016;32:93-100. https://doi.org/10.1016/j.jcrc.2015.11.013
  • Rezaei N, Keshavarz-Fathi M. Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives: Elsevier Science; 2018
    https://www.elsevier.com/books/vaccines-for-cancer-immunotherapy/rezaei/978-0-12-814039-0
  • Keshavarz-Fathi M, Keshavarz-Fathi M, Rezaei N. Cancer Immunology. In: Rezaei N, editor. Encyclopedia of Infection and Immunity. Oxford: Elsevier; 2022. p. 277-95.
    https://doi.org/10.1016/B978-0-12-818731-9.00083-5
  • Moossavi S, Fehr K, Maleki H, et al, *Keshavarz-Fathi M*, Rezaei N. Prevention of COVID-19: Preventive Strategies for General Population, Healthcare Setting, and Various Professions. Adv Exp Med Biol. 2021;1318:575-604.
    https://doi.org/10.1007/978-3-030-63761-3_32
  • Rezaei N, Ashkevarian S, Fathi MK, Hanaei S, Kolahchi Z, Ladi Seyedian SS, et al. Introduction on Coronavirus Disease (COVID-19) Pandemic: The Global Challenge. Adv Exp Med Biol. 2021;1318:1-22.
    https://doi.org/10.1007/978-3-030-63761-3_1
  • Nowroozi A, Razi S, Sahu KK, Grizzi F, Arends J, Keshavarz-Fathi M, et al. COVID-19 in Patients with Cancer. Adv Exp Med Biol. 2021;1318:315-31.
    https://doi.org/10.1007/978-3-030-63761-3_18
  • Aryan Z, Keshavarz-Fathi M, Mellstedt H, Rezaei N. Cancer Immunotherapy Confers a Global Benefit. In: Rezaei N. (eds) Cancer Immunology. Springer; 2020. p. 1-39.
    https://doi.org/10.1007/978-3-030-57949-4_1
  • Ebadi M, Keshavarz-Fathi M, Zeng Y, Gkotzamanidou M, Rezaei N. Immunopathology and Immunotherapy of Hodgkin Lymphoma. In: Rezaei N. (eds) Cancer Immunology. Springer; 2020. p. 135-157.
    https://doi.org/10.1007/978-3-030-57949-4_6
  • Saghazadeh A, Keshavarz-Fathi M, Delavari F, Rezaei N. Radiation and Immunity: Hand in Hand from Tumorigenesis to Therapeutic Targets. In: Rezaei N. (eds) Cancer Immunology. Springer; 2020. p. 587-596.
    https://doi.org/10.1007/978-3-030-50287-4_30
  • Mahdavi Sharif P, Keshavarz-Fathi M, Rezaei N. Biomarkers for Immune Checkpoint Inhibitors. In: Rezaei N. (eds) Cancer Immunology. Springer; 2020. p. 449-463.
    https://doi.org/10.1007/978-3-030-50287-4_25
  • Hemmati S, Keshavarz-Fathi M, Razi S, Rezaei N. Gene Therapy and Genetic Vaccines. In: Rezaei N. (eds) Cancer Immunology. Springer; 2020. p. 129-142.
    https://doi.org/10.1007/978-3-030-50287-4_7
  • Balibegloo M, Keshavarz-Fathi M, Rezaei N. Tumor Antigen Identification for Cancer Immunotherapy. In: Rezaei N. (eds) Cancer Immunology. Springer; 2020. p. 53-59.
    https://doi.org/10.1007/978-3-030-50287-4_4
  • Ghaffari N, Razi S, Keshavarz-Fathi M, Rezaei N. Immunopathology and Immunotherapy for Breast Cancer. In: Rezaei N. (eds) Cancer Immunology. Springer; 2020. p.
    541-555. https://doi.org/10.1007/978-3-030-57949-4_21
  • Aalaei-Andabili SH, Amini N, Delavari F, Keshavarz-Fathi M, Basith S, Choi S, Rezaei N. Toll-Like Receptor Pathway and Its Targeting in Treatment of Cancers. In: Rezaei N. (eds) Cancer Immunology. Springer; 2020. p. 313-325.
    https://doi.org/10.1007/978-3-030-50287-4_16
  • Hirbod-Mobarakeh A, Shabani M, Keshavarz-Fathi M, Delavari F, Amirzargar AA, Nikbin B, et al. Immunogenetics of Cancer. 
    Cancer Immunology: Springer; 2020. p. 417-78.     https://doi.org/10.1007/978-3-030-30845-2_20
  • Rezaei N, Aalaei-Andabili SH, Amini N, Delavari F, Keshavarz-Fathi M, Kaufman HL. Introduction on cancer immunology and immunotherapy. 
    Cancer immunology: Springer; 2020. p. 1-9.     https://doi.org/10.1007/978-3-030-30845-2_1
  • Keshavarz-Fathi M, Rezaei N. Chapter 1 - Cancer Immunology. In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for Cancer Immunotherapy: Academic Press; 2019. p. 1-17.
    https://doi.org/10.1016/B978-0-12-814039-0.00001-1
  • Keshavarz-Fathi M, Rezaei N. Chapter 2 - Immunotherapeutic Approaches in Cancer. In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for Cancer Immunotherapy: Academic Press; 2019. p. 19-44.
    https://doi.org/10.1016/B978-0-12-814039-0.00002-3
  • Keshavarz-Fathi M, Rezaei N. Chapter 3 - Vaccines, Adjuvants, and Delivery Systems. In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for Cancer Immunotherapy: Academic Press; 2019. p. 45-59.
    https://doi.org/10.1016/B978-0-12-814039-0.00003-5
  • Keshavarz-Fathi M, Rezaei N. Chapter 6 - Personalized Cancer Vaccine. In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for Cancer Immunotherapy: Academic Press; 2019. p. 81-9.
    https://doi.org/10.1016/B978-0-12-814039-0.00006-0
  • Razi S, Keshavarz-Fathi M. Chapter 7 - Whole Tumor Cell Vaccine for Cancer. In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for Cancer Immunotherapy: Academic Press; 2019. p. 91-9.
    https://doi.org/10.1016/B978-0-12-814039-0.00007-2
  • Keshavarz-Fathi M, Rezaei N. Chapter 8 - Peptide and Protein Vaccines for Cancer. In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for Cancer Immunotherapy: Academic Press; 2019. p. 101-16.
    https://doi.org/10.1016/B978-0-12-814039-0.00008-4
  • Valilou SF, Keshavarz-Fathi M. Chapter 10 - Genetic Vaccine for Cancer. In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for Cancer Immunotherapy: Academic Press; 2019. p. 129-43.
    https://doi.org/10.1016/B978-0-12-814039-0.00010-2
  • Keshavarz-Fathi M, Rezaei N. Chapter 11 - Candidate Cancers for Vaccination. In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for Cancer Immunotherapy: Academic Press; 2019. p. 145-52.
    https://doi.org/10.1016/B978-0-12-814039-0.00011-4
  • Keshavarz-Fathi M, Rezaei N. Chapter 12 - Obstacles in the Development of Therapeutic Cancer Vaccines. In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for Cancer Immunotherapy: Academic Press; 2019. p. 153-60.
    https://doi.org/10.1016/B978-0-12-814039-0.00012-6
  • Keshavarz-Fathi M, Rezaei N. Chapter 13 - Combination Therapy: Cancer Vaccines and Other Therapeutics. In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for Cancer Immunotherapy: Academic Press; 2019. p. 161-70.
    https://doi.org/10.1016/B978-0-12-814039-0.00013-8
  • Keshavarz-Fathi M, Rezaei N. Chapter 14 - Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines. In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for Cancer Immunotherapy: Academic Press; 2019. p. 171-6. https://doi.org/10.1016/B978-0-12-814039-0.00014-X


Administrative credits

  • Executive Activity - 2023

    2.40

  • Executive Activity - 2022

    6.50

  • Executive Activity - 2021

    7.20

  • Executive Activity - 2020

    8.40

  • Executive Activity - 2019

    8.40

  • Executive Activity - 2018

    8.40

  • Executive Activity - 2017

    8.40

  • Executive Activity - 2017

    8.40

  • Executive Activity - 2016

    8.40

Participation credits

We use cookies to personalize your experience.

We use essential cookies to keep things secure and optional analytics cookies to understand how the site is used.

View privacy policy
You can change this anytime in settings.

We use cookies to personalize your experience.

We use essential cookies to keep things secure and optional analytics cookies to understand how the site is used.

View privacy policy
You can change this anytime in settings.